BJS
@bjsurgery.bsky.social
BJS is the premier peer-reviewed surgical journal in Europe, with an Impact Factor of 8.7. #LeadingSurgicalEducation
Vermaas M, Doornebosch P G, Intven M P W, Crolla R M P H, Festen S, Verseveld M, Roomer R, Verdaasdonk E, Brokelman W J A, Koomen N
November 15, 2025 at 10:12 AM
Vermaas M, Doornebosch P G, Intven M P W, Crolla R M P H, Festen S, Verseveld M, Roomer R, Verdaasdonk E, Brokelman W J A, Koomen N
..Peeters K C M J, Boonstra J J, van Westreenen H L, de Vos tot Nederveen Cappel W H, Burger J W A, Bloemen J G, Talsma A K, Bosker R B, Tuynman J B, Hompes R, Hoff C, Koopal S A, Pronk A, Schiphorst A H W, de Wilt J H W, Bremers A J A, Wasowicz D K, Zimmerman D D E, Schreurs W H, Dunker M S, ...
November 15, 2025 at 10:12 AM
..Peeters K C M J, Boonstra J J, van Westreenen H L, de Vos tot Nederveen Cappel W H, Burger J W A, Bloemen J G, Talsma A K, Bosker R B, Tuynman J B, Hompes R, Hoff C, Koopal S A, Pronk A, Schiphorst A H W, de Wilt J H W, Bremers A J A, Wasowicz D K, Zimmerman D D E, Schreurs W H, Dunker M S, ...
Work by Geubels Barbara M, Grotenhuis Brechtje A, van den Esschert Aart-Jan, Lambregts Doenja M J, Maas Monique, Marijnen Corrie A M, Beets-Tan Regina G H, Beets Geerard L, Dutch Watch-and-Wait consortium, van Leerdam M E, van Triest B, Melenhorst J, Breukink S O, Sonneveld D J A, van den Broek J J
November 15, 2025 at 10:12 AM
Work by Geubels Barbara M, Grotenhuis Brechtje A, van den Esschert Aart-Jan, Lambregts Doenja M J, Maas Monique, Marijnen Corrie A M, Beets-Tan Regina G H, Beets Geerard L, Dutch Watch-and-Wait consortium, van Leerdam M E, van Triest B, Melenhorst J, Breukink S O, Sonneveld D J A, van den Broek J J
Implementing W&W across high-volume-robust organ preservation and survival rates, and stable regrowth/metastasis rates across cohorts
More recent cohorts showed increased use of
TME for persistent residual disease, likely reflecting broader inclusion of near-complete responders
More recent cohorts showed increased use of
TME for persistent residual disease, likely reflecting broader inclusion of near-complete responders
November 15, 2025 at 10:12 AM
Implementing W&W across high-volume-robust organ preservation and survival rates, and stable regrowth/metastasis rates across cohorts
More recent cohorts showed increased use of
TME for persistent residual disease, likely reflecting broader inclusion of near-complete responders
More recent cohorts showed increased use of
TME for persistent residual disease, likely reflecting broader inclusion of near-complete responders
Local regrowth: 3-year incidence of 23%; organ preservation: 3-year rate reported; distant metastases: 3-year rate reported; overall survival: 97% at 3 years.
November 15, 2025 at 10:11 AM
Local regrowth: 3-year incidence of 23%; organ preservation: 3-year rate reported; distant metastases: 3-year rate reported; overall survival: 97% at 3 years.
Registry analysis (2004–2022); three chronological cohorts compared. Outcomes include local regrowth, distant metastases, overall survival, and organ preservation.
November 15, 2025 at 10:11 AM
Registry analysis (2004–2022); three chronological cohorts compared. Outcomes include local regrowth, distant metastases, overall survival, and organ preservation.
Assess nationwide Watch-and-Wait (W&W) for rectal cancer across 18 high-volume Dutch hospitals in patients displaying a good response after (chemo)radiotherapy.
November 15, 2025 at 10:11 AM
Assess nationwide Watch-and-Wait (W&W) for rectal cancer across 18 high-volume Dutch hospitals in patients displaying a good response after (chemo)radiotherapy.
🥤 Post-op care focuses on tailored maintenance (≤2–2.5 L/day), early oral intake, and aiming for near-zero or negative fluid balance to reduce complications
Work by Michael Ess, Dileep N Lobo @DL08OMD
Work by Michael Ess, Dileep N Lobo @DL08OMD
November 13, 2025 at 6:27 PM
🥤 Post-op care focuses on tailored maintenance (≤2–2.5 L/day), early oral intake, and aiming for near-zero or negative fluid balance to reduce complications
Work by Michael Ess, Dileep N Lobo @DL08OMD
Work by Michael Ess, Dileep N Lobo @DL08OMD
⚖️ Intraoperatively, it advocates balanced crystalloids over 0.9% saline, low-rate background infusions, and goal-directed boluses to avoid salt–water overload
🩸 For bleeding, early 1:1:1 blood product transfusion is advised
🩸 For bleeding, early 1:1:1 blood product transfusion is advised
November 13, 2025 at 6:27 PM
⚖️ Intraoperatively, it advocates balanced crystalloids over 0.9% saline, low-rate background infusions, and goal-directed boluses to avoid salt–water overload
🩸 For bleeding, early 1:1:1 blood product transfusion is advised
🩸 For bleeding, early 1:1:1 blood product transfusion is advised
IV fluids are drugs — both deficit and overload worsen outcomes, yet perioperative prescribing is often overlooked and delegated to juniors
🩺 The paper stresses ABCDE assessment and clear indication (resuscitation, replacement, maintenance), plus better pre-op hydration with “SipTilSend”
🩺 The paper stresses ABCDE assessment and clear indication (resuscitation, replacement, maintenance), plus better pre-op hydration with “SipTilSend”
November 13, 2025 at 6:27 PM
IV fluids are drugs — both deficit and overload worsen outcomes, yet perioperative prescribing is often overlooked and delegated to juniors
🩺 The paper stresses ABCDE assessment and clear indication (resuscitation, replacement, maintenance), plus better pre-op hydration with “SipTilSend”
🩺 The paper stresses ABCDE assessment and clear indication (resuscitation, replacement, maintenance), plus better pre-op hydration with “SipTilSend”
Sex-specific considerations may be necessary when monitoring and managing patients with small AAA.
Work by Ngai Heather, Olson Sydney, Curci John, Kazmers Andris, Shames Murray, Tsai Shirling, Blackwelder William, Matsumura Jon S, Baxter Bernard Timothy, Terrin Michael, Albrecht Jennifer S
Work by Ngai Heather, Olson Sydney, Curci John, Kazmers Andris, Shames Murray, Tsai Shirling, Blackwelder William, Matsumura Jon S, Baxter Bernard Timothy, Terrin Michael, Albrecht Jennifer S
November 12, 2025 at 8:50 AM
Sex-specific considerations may be necessary when monitoring and managing patients with small AAA.
Work by Ngai Heather, Olson Sydney, Curci John, Kazmers Andris, Shames Murray, Tsai Shirling, Blackwelder William, Matsumura Jon S, Baxter Bernard Timothy, Terrin Michael, Albrecht Jennifer S
Work by Ngai Heather, Olson Sydney, Curci John, Kazmers Andris, Shames Murray, Tsai Shirling, Blackwelder William, Matsumura Jon S, Baxter Bernard Timothy, Terrin Michael, Albrecht Jennifer S
These data suggest that, within the small-AAA range, women experience faster aneurysm expansion and differ in baseline risk factor profiles, including less frequent use of cardioprotective medication and a more frequent family history.
November 12, 2025 at 8:50 AM
These data suggest that, within the small-AAA range, women experience faster aneurysm expansion and differ in baseline risk factor profiles, including less frequent use of cardioprotective medication and a more frequent family history.
Aneurysm growth: higher in women (0.21 vs 0.16 cm/year); Medication use (statins, antiplatelets): ↓ in women; Family history of AAA: ↑ in women.
November 12, 2025 at 8:50 AM
Aneurysm growth: higher in women (0.21 vs 0.16 cm/year); Medication use (statins, antiplatelets): ↓ in women; Family history of AAA: ↑ in women.
Retrospective cohort study using N-TA3CT RCT data; baseline AAA ≤4.5 cm and at least one follow-up CT; outcomes include growth rate, patient characteristics, safety/adverse events, and clinical outcomes.
November 12, 2025 at 8:49 AM
Retrospective cohort study using N-TA3CT RCT data; baseline AAA ≤4.5 cm and at least one follow-up CT; outcomes include growth rate, patient characteristics, safety/adverse events, and clinical outcomes.
Investigate sex differences in characteristics, aneurysm growth, and outcomes among adults with small AAA in N-TA3 clinical trial (secondary analysis).
November 12, 2025 at 8:49 AM
Investigate sex differences in characteristics, aneurysm growth, and outcomes among adults with small AAA in N-TA3 clinical trial (secondary analysis).
... Puccetti Francesco, Giacopuzzi Simone, Gisbertz Suzanne S, So Jimmy B Y, Ruurda Jelle P, van der Sluis Pieter S L, Lagarde Sjoerd M, van Sandick Johanna W, Wijnhoven Bas P L; Other Members of the IGCA European Chapter Collaborative Group on Staging Laparoscopy for Gastric Cancer
November 9, 2025 at 6:55 PM
... Puccetti Francesco, Giacopuzzi Simone, Gisbertz Suzanne S, So Jimmy B Y, Ruurda Jelle P, van der Sluis Pieter S L, Lagarde Sjoerd M, van Sandick Johanna W, Wijnhoven Bas P L; Other Members of the IGCA European Chapter Collaborative Group on Staging Laparoscopy for Gastric Cancer
Work by van Hootegem Sander J M, Guchelaar Niels A D, van der Sluis Karen, Triemstra Lianne, Mönig Stefan P, Rawicz-Pruszyński Karol, Rosati Riccardo, Morgagni Paolo, Erodotou Maria, Solaini Leonardo, De Manzoni Giovanni, Polkowski Wojciech, ...
November 9, 2025 at 6:55 PM
Work by van Hootegem Sander J M, Guchelaar Niels A D, van der Sluis Karen, Triemstra Lianne, Mönig Stefan P, Rawicz-Pruszyński Karol, Rosati Riccardo, Morgagni Paolo, Erodotou Maria, Solaini Leonardo, De Manzoni Giovanni, Polkowski Wojciech, ...
💡These data provide practical, Europe-wide guidance on patient selection and procedure structuring, emphasizing high-risk biology and clarifying junctional tumour scenarios.
November 9, 2025 at 6:55 PM
💡These data provide practical, Europe-wide guidance on patient selection and procedure structuring, emphasizing high-risk biology and clarifying junctional tumour scenarios.
📊 Indications: Consensus for cT3–4, cN+, poorly cohesive, or radiological PM risk; Junctional tumours — Siewert III: yes; Siewert I: no; Siewert II: conditional on gastric involvement;.
111 experts from 16 countries participated.
111 experts from 16 countries participated.
November 9, 2025 at 6:52 PM
📊 Indications: Consensus for cT3–4, cN+, poorly cohesive, or radiological PM risk; Junctional tumours — Siewert III: yes; Siewert I: no; Siewert II: conditional on gastric involvement;.
111 experts from 16 countries participated.
111 experts from 16 countries participated.